Dare Bioscience Inc
Change company Symbol lookup
Select an option...
DARE Dare Bioscience Inc
COKE Coca-Cola Consolidated Inc
KALU Kaiser Aluminum Corp
SEED Origin Agritech Ltd
DFFN Diffusion Pharmaceuticals Inc
PCSB PCSB Financial Corp
BHB Bar Harbor Bankshares
EH Ehang Holdings Ltd
CNSL Consolidated Communications Holdings Inc
WLFC Willis Lease Finance Corp
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Closing Price
$0.90
Day's Change
0.0236 (2.69%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9199
Day's Low
0.84
Volume
(Light)
Volume:
82,158

10-day average volume:
141,735
82,158

Company Profile

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
40.19x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

March 2020
Current Month
256.5K
Previous Month
231.9K
Percent of Float
1.19%
Days to Cover
1.2432 Days

Share Information

DARE is in a share class of common stock
Float
21.5M
Shares Outstanding
24.7M
Institutions Holding Shares
12
3.35%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • William H. RastetterChmn.
  • Sabrina Martucci JohnsonPres.
  • Gregg D. BeloffCFO
  • Lisa Walters-HoffertCFO
  • Jame O'NeillCAO

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.